Crenolanib for treating FLT3 mutated proliferative disorders
AssigneeArog Pharmaceuticals, Inc.
InventorVinay K. Jain
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
Claims43
A method for treating a FLT3 mutated hematologic malignant proliferative disorder in a human patient comprising administering to the human patient having a FLT3 mutated hematologic malignant proliferative disorder a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof.
A method for treating a human patient suffering from a hematologic malignant proliferative disease comprising:
- identifying the patient in need of therapy for the hematologic malignant proliferative disease having deregulated FLT3 receptor tyrosine kinase activity;
- and
- administering to the patient in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof, wherein the proliferative disease is selected from at least one of leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, or idiopathic hypereosinophilic syndrome (HES).
A method for treating a human patient suffering from leukemia comprising:
- obtaining a sample from the human patient suspected of having leukemia;
- determining from the human patient sample that the patient has a deregulated FLT3 receptor tyrosine kinase;
- and
- administering to the human patient in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof, wherein the leukemia is characterized by deregulated FLT3 receptor tyrosine kinase activity.
A method for specifically inhibiting a deregulated receptor tyrosine kinase comprising:
- obtaining a patient sample;
- determining which receptor tyrosine kinases are deregulated;
- and
- administering to the patient with a hematologic malignant proliferative disease and in need of such treatment a therapeutically effective amount of crenolanib or a salt thereof, wherein the deregulated receptor tyrosine kinase is a FLT3 receptor tyrosine kinase.
A method for treating a human patient with a FLT3 mutated hematologic malignant proliferative disease comprising:
- obtaining a sample from the human patient;
- determining if the human patient that has become resistant to prior tyrosine kinase inhibitors or chemotherapy;
- and
- administering to the human patient a therapeutically effective amount of Crenolanib or a salt thereof to overcome the resistance to the prior protein tyrosine kinase inhibitors.
Dependencies are inferred from the claim text.